MMS

Rating neutralAI Memo

MAXIMUS

As of 2026-09-25/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

FY2027 guidance tests earnings recovery • 2026-11-30

Base target: $58 / p=50% prob

Biggest risk

The contract modification reduced FY2026 earnings and free-cash-flow guidance visibility. Federal Services revenue fell year over year as prior-year disaster work and clinical surges did not recur; the large sales pipeline is not a revenue commitment. [#SEC-8K-2026-08-06]

Invalidation

Break below $42 or thesis failure.

What would change my mind?

Q3 adjusted EBITDA margin rose to 15.0% from 14.7% a year earlier despite lower revenue. If the temporary federal incentive pause ends as scheduled and signed awards convert, low apparent earnings multiples could support a rerating. [#SEC-8K-2026-08-06]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-25

Base target

$58

p=50%

Bull target

$70

p=25%

Bear target

$42

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Federal contract modification pressures near-term profit
Contract pipeline conversion and productivity gains
Q3 adjusted EBITDA margin rose to 15.0% from 14.7% a year earlier despite lower revenue.

BearKey bullets

FY2026 adjusted EPS guidance is $7.90–$8.20 and free-cash-flow guidance is $425 million–$475 million following the customer-directed modification.
[#SEC-8K-2026-08-06]
Federal revenue faces difficult comparisons as prior-year disaster support and temporary clinical volumes fade.

WatchKey bullets

FY2027 guidance tests earnings recovery

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $58 (p=50%)

Target spread vs base: +21% / -28%

Scenario probabilities

Bull Target: $70 (p=25%)Base Target: $58 (p=50%)Bear Target: $42 (p=25%)

Commentary

The available news is mainly the August earnings release, not a fresh September catalyst. Q3 execution was solid, but reduced earnings visibility offsets it. Current price reaction, analyst revisions, options, short-interest, employee and social measures are unavailable; zero sentiment fields denote missing data, not neutral readings.

As of 2026-09-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Federal contract modification pressures near-term profit
Contract pipeline conversion and productivity gains

Scenarios

Bull Target (Scenario probability)

$70 / p=25% prob

Base Target (Scenario probability)

$58 / p=50% prob

Bear Target (Scenario probability)

$42 / p=25% prob

Analysis 2026-09-25 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-30
FY2027 guidance tests earnings recovery
Management expects to issue formal FY2027 guidance in November. It should clarify whether the contract modification, sustained efficiency gains, and U.S. Services growth can support a recovery; no recovery is assumed here. [#PR-EARNINGS-2026-08-13]
Prob 80.00% • Move 6.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Federal contract modification pressures near-term profit
2026-12-31
A customer-directed modification affecting the VA medical-exam program began July 1 and runs through December 31, 2026. Maximus lowered FY2026 adjusted EPS guidance to $7.90–$8.20 and expects a 16.5%–17.0% U.S. Federal Services operating margin. Whether the incentive pause ends as scheduled is the key near-term risk. [#SEC-8K-2026-08-06] [#PR-EARNINGS-2026-08-13]
Prob 85% • Move -7% • Priced-in 70%

Long-term Catalysts

Months to a year

Contract pipeline conversion and productivity gains
2027-09-30
At June 30, Maximus reported $1.25 billion of year-to-date signed awards, $1.35 billion awarded but unsigned, and a $50.4 billion sales pipeline. Automation and AI-enabled tools helped Q3 margins, but much of the pipeline consists of tracked opportunities rather than booked revenue. Conversion and durable margin gains remain unproven. [#SEC-8K-2026-08-06]
Prob 55% • Move 12% • Priced-in 30%

Risks

FY2026 adjusted EPS guidance is $7.90–$8.20 and free-cash-flow guidance is $425 million–$475 million following the customer-directed modification. [#SEC-8K-2026-08-06]
Federal revenue faces difficult comparisons as prior-year disaster support and temporary clinical volumes fade. [#SEC-8K-2026-08-06]
Pipeline opportunities may not convert into signed, profitable contracts; Outside the U.S. Q3 operating margin was 0.9%. [#SEC-8K-2026-08-06]
The VA medical-exam incentive pause could last longer or have a larger FY2027 profit effect than expected. [#SEC-8K-2026-08-06] [#PR-EARNINGS-2026-08-13]

Peers

Symbol	Summary
ABM	Similar-sized services company, but its facilities-services mix is a loose comparison for Maximus's government-program contracts.
CBZ	Similar market-cap reference; its professional-services mix limits direct operating comparability.
HURN	Consulting-services reference, but not a close peer for Maximus's federal and benefits-program contract economics.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-25

Loading AI feed…

Symbol

Summary

ABM

Similar-sized services company, but its facilities-services mix is a loose comparison for Maximus's government-program contracts.

CBZ

Similar market-cap reference; its professional-services mix limits direct operating comparability.

HURN

Consulting-services reference, but not a close peer for Maximus's federal and benefits-program contract economics.